Phase Ib Study: Evaluating CUE-102 in Recurrent Glioblastoma

Dana-Farber is assessing the safety and recommended dosing of CUE-102—a WT-1-pHLA-IL2-Fc fusion protein—in HLA-A*0201-positive glioblastoma patients at first recurrence, with daily dosing in 21-day cycles and imaging every 9 weeks to monitor response.